Cleveland Clinic | Strategic Alliance Partnership

Yael Mauer, MD, MPH, discusses the patient population who benefits most from interventions with glucagon-like peptide-1 (GLP-1) therapies and explores the underlying mechanisms at work.

Stacey Ehrenberg, MD, discusses the lacking data and potential implications of using glucagon-like peptide-1 (GLP-1) receptor agonists during pregnancy for patients with diabetes and/or obesity.

Diana Isaacs, PharmD, chair of a recent Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic, details the up-and-coming therapies impacting the scope of treatment in diabetes, obesity, and cardiometabolic health, as well as their associated challenges.

Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions.

Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.

Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES, Cleveland Clinic, discusses how GLP-1 receptor agonists have evolved in the treatment landscape of diabetes and obesity at an Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic.

Marisa McGinley, DO, explains how technology can help improve access to multiple sclerosis (MS) care.

Daniel Ontaneda, MD, PhD, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 chair, discussed what attendees can expect at this year's meeting, as well as how the theme of "Breaking Barriers in MS" will be implemented.

Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.

Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.

Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, discusses methods for identifying patients with indolent systemic mastocyctosis (ISM) using health claims data.

Experts explain how diabetes is diagnosed during pregnancy, how treatment differs from that of nonpregnant individuals, the importance of diabetes technology education, and how things change postpartum.

Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, suggests that some patients with indolent systemic mastocytosis (ISM) may be progressing at a faster rate than expected, and will need to be monitored and started on appropriate therapies.

Brian Mullen, PhD, head of innovation and product at The Clinic by Cleveland Clinic, shares his expertise in providing easy-to-use digital health platforms for patients, while maintaining the cost-effectiveness of these innovations.

Brian Mullen, PhD, head of innovation and product at The Clinic by Cleveland Clinic, discusses the implementation of digital health tools and strategies made by The Clinic and what these improvements mean for its patients.

Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, address the impact of effective treatments of chronic cough on patient quality of life (QOL).

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, discusses the important need for chronic cough therapies and what issues with current treatments should be addressed by next-generation medications.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the challenges of treating chronic cough.

Roxana Siles, MD, FAAAAI, codirector of the Asthma Center at Cleveland Clinic, discusses the challenges of managing patients with chronic cough.

Eligible patients who are not waitlisted for kidney transplants lose profound opportunities and are subject to racial and socioeconomic disparities regarding waitlist placement, a study showed.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

The group-based Sleep Apnea Management clinic at Cleveland Clinic's Sleep Disorders Center increased criteria-met adherence to positive airway pressure (PAP) therapy by 20% in patients with obstructive sleep apnea (OSA).

Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.

Survey also shows many struggling with pandemic-related mental health issues, particularly younger Americans.

The American Journal of Managed Care® recently hosted a Peer Exchange that featured discussion among a panel of expert cardiologists and managed care decision makers regarding how cardiovascular outcome trial results are impacting the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure and how these drugs are shaping heart failure outcomes for patients. Panelists were Nihar R. Desai, MD, MPH, assistant professor of medicine in the cardiovascular medicine section of the Yale School of Medicine and investigator in the Center for Outcomes Research and Evaluation in New Haven, Connecticut; Jaime Murillo, MD, national senior director of cardiology at UnitedHealthcare in Fort Lauderdale, Florida; and Steven Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Cleveland, Ohio. The moderator was Neil B. Minkoff, MD, chief medical officer of Coeus Consulting Group in Sudbury, Massachusetts.

The 18th annual summit will bring together speakers and leaders with actionable insights for healthcare evolution.

In July, Cleveland Clinic completed their 2000th heart and 2000th lung transplantations as the third program in the country to reach this landmark

Cleveland Clinic and Aetna are forming an accountable care organization.